Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.

@article{Palumbo2010MelphalanPT,
  title={Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.},
  author={Antonio Palumbo and Alessandra Larocca and Mariella Genuardi and Katarzyna Kotwica and Francesca Gay and Davide Rossi and Giulia Benevolo and Valeria Magarotto and Federica Cavallo and Sara Bringhen and Cecilia Rus and Luciano Masini and Massimo Iacobelli and Gianluca Gaidano and Constantine Mitsiades and Kenneth A. Anderson and Mario Boccadoro and Paul Richardson},
  journal={Haematologica},
  year={2010},
  volume={95 7},
  pages={1144-9}
}
BACKGROUND Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and relapsed/refractory multiple myeloma, and to determine its safety and tolerability as part of this regimen. DESIGN… CONTINUE READING